Health-economic evaluation of fluocinolone acetonide 190 µg implant in people with diabetic macular edema

Objectives: To assess healthcare resource use and costs of treating people with clinically significant diabetic macular edema (DME) with fluocinolone acetonide (FAc) 190 µg intravitreal implant in routine clinical practice. Methods: The retrospective Iluvien Clinical Evidence (ICE-UK) study collecte...

Full description

Saved in:
Bibliographic Details
Published in:Current medical research and opinion 2017-10, Vol.33 (sup2), p.45-52
Main Authors: Holden, Sarah E., Currie, Craig J., Owens, David R.
Format: Article
Language:English
Subjects:
Aged
Cost-Benefit Analysis
Dexamethasone - administration & dosage
diabetic macular edema
Diabetic Retinopathy - drug therapy
Diabetic Retinopathy - economics
Drug Implants
Female
Fluocinolone acetonide
Fluocinolone Acetonide - economics
Fluocinolone Acetonide - therapeutic use
Glucocorticoids - economics
Glucocorticoids - therapeutic use
healthcare cost
healthcare resource use
Humans
Injections
Macular Edema - drug therapy
Macular Edema - economics
Male
Middle Aged
retrospective
Retrospective Studies
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives: To assess healthcare resource use and costs of treating people with clinically significant diabetic macular edema (DME) with fluocinolone acetonide (FAc) 190 µg intravitreal implant in routine clinical practice. Methods: The retrospective Iluvien Clinical Evidence (ICE-UK) study collected data on people prescribed the FAc implant in any one of 13 ophthalmology centers between April 1, 2013 and April 15, 2015. Data were collected for 12 months before and after implantation. Standard UK costs were attributed to healthcare resource use. Results: In total, 208 people contributing 233 FAc-treated eyes were selected. Mean age was 68.1 years and 62% were male. The mean (standard deviation, SD) number of anti-vascular endothelial growth factor (anti-VEGF) injections per FAc treated eye in the 12 months prior to implant was 2.8 (2.5), decreasing to 0.6 (1.4) for the same period after implant (p 
ISSN:0300-7995
1473-4877
DOI:10.1080/03007995.2017.1366663